Patents Examined by Michael Szperka
-
Patent number: 11827719Abstract: The disclosure provides a pharmaceutical composition containing an anti-IgE antibody that suppresses the production of allergen-specific IgE antibodies and methods of use thereof.Type: GrantFiled: April 6, 2020Date of Patent: November 28, 2023Assignees: HOBIT GENOMIX, INC., NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENTInventors: Hirohisa Saito, Kenji Matsumoto, Hideaki Morita, Go Ichien, Yasuhiko Koezuka, Kimishige Ishizaka
-
Patent number: 11820814Abstract: Provided herein are novel isolated, synthetic or recombinant antibodies and fragments thereof specific for factor H, or nucleic acids or vectors encoding such antibodies and fragments. Further provided herein is the use of such antibodies, fragments, nucleic acids or vectors for inhibiting complement activation and treatment of disorders associated with complement activation.Type: GrantFiled: July 17, 2020Date of Patent: November 21, 2023Assignees: GEMINI THERAPEUTICS SUB, INC., STICHTING SANQUIN BLOEDVOORZIENINGInventors: Scott Lauder, Tom Purcell, Sridhar Govindarajan, Taco Willem Kuijpers, Diana Wouters, Maria Clara Brouwer, Richard Benjamin Pouw, Taede Rispens, Ilse Jongerius, Gillian Dekkers
-
Patent number: 11813307Abstract: The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as “polypeptides of the invention”, and “immunoglobulin(s) of the invention”, respectively).Type: GrantFiled: June 4, 2018Date of Patent: November 14, 2023Assignees: MERCK PATENT GMBH, ABLYNX NVInventors: Soren Steffensen, Gerald Beste, Hans Guehring, Lars Toleikis, Christoph Ladel, Sven Lindemann, Roland Kellner, Ralf Guenther
-
Patent number: 11814421Abstract: The invention pertains to a polypeptide comprising a truncated von Willebrand Factor (VWF) and a half-life extending moiety, for use in the treatment of a blood coagulation disorder, said treatment comprising administering the polypeptide to a subject having a blood coagulation disorder and having endogenous Factor VIII (FVIII), wherein the activity level of endogenous FVIII in said subject before treatment with said polypeptide is reduced relative to the activity level of FVIII in normal human plasma (NHP) provided that the activity level of endogenous FVIII in said subject is at least 0.5% of the activity level of endogenous FVIII in normal human plasma (NHP), wherein the polypeptide is capable of binding to endogenous FVIII and wherein the endogenous FVIII level is increased following administration of said polypeptide.Type: GrantFiled: November 10, 2017Date of Patent: November 14, 2023Assignee: CSL BEHRING LENGNAU AGInventors: Stefan Schulte, Thomas Weimer, Sabine Pestel, Hubert Metzner, Steve Dower
-
Patent number: 11795211Abstract: The present disclosure relates to methods for generating broadly neutralizing bovine anti-HIV Env antibodies, compositions comprising the broadly neutralizing bovine antibodies, and methods of treatment or prevention of HIV using the broadly neutralizing bovine antibodies. In certain embodiments, a broadly neutralizing bovine antibody comprises a polyclonal F(ab) or F(ab?)2 fragment. In certain embodiments, a broadly neutralizing bovine antibody comprises a humanized bovine monoclonal antibody.Type: GrantFiled: July 12, 2018Date of Patent: October 24, 2023Assignees: International AIDS Vaccine Initiative, The Scripps Research Institute, THE TEXAS A&M UNIVERSITY SYSTEMInventors: Devin Sok, Dennis R. Burton, Vaughn V. Smider, Ian Wilson, Michael Criscitiello, Waithaka Mwangi
-
Patent number: 11787851Abstract: The present invention provides codon optimized Factor VIII sequences, vectors and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides. The present invention also provides methods of treating bleeding disorders such as hemophilia comprising administering to the subject a codon optimized Factor VIII nucleic acid sequence or the polypeptide encoded thereby.Type: GrantFiled: June 25, 2019Date of Patent: October 17, 2023Assignee: BIOVERATIV THERAPEUTICS INC.Inventors: Siyuan Tan, Robert T. Peters
-
Patent number: 11787849Abstract: The invention describes kit of parts of polypeptides comprising: a) a peptide comprising: a1) an MHC class II T cell epitope or a CD1 d-restricted NKT cell epitope, and a2) immediately adjacent to said epitope or separated by at most 7 amino acids from said epitope a [CST]-X(2)-C [SEQ ID NO:7] or C-X(2)-[CST] [SEQ ID NO:8] oxidoreductase motif sequence, and b) a polypeptide comprising: b1) a therapeutic protein and b2) the epitope defined in a1), wherein the epitope sequence is a sequence which differs from the sequence of the protein of b1). The therapeutic protein, in combination with the peptide, is used to prevent an immune response against the therapeutic protein.Type: GrantFiled: September 23, 2016Date of Patent: October 17, 2023Assignee: IMCYSE SAInventors: Jean-Marie Saint-Remy, Luc Vander Elst, Vincent Carlier
-
Patent number: 11789019Abstract: The present application discloses proteins or peptides and methods of using such proteins or peptides to evaluate the immune status of a patient. In one embodiment, proteins or peptides may be used to detect endogenous calnexin specific CD4 T cells. In one preferred embodiment, the proteins or peptides may comprise peptide-MHCII tetramers (pMHC tetramers).Type: GrantFiled: August 1, 2019Date of Patent: October 17, 2023Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Bruce Steven Klein, Marcel Wuethrich
-
Patent number: 11787874Abstract: The application relates to unique FX binding molecules, such as antibodies and fragments thereof which are useful in the treatment of haemophilia.Type: GrantFiled: November 15, 2018Date of Patent: October 17, 2023Assignee: Novo Nordisk A/SInventors: Jacob Lund, Karina Thorn, Mikkel Nors Harndahl, Marie-Ange Buyse, Evelyn De Tavernier, Soren Steffensen
-
Patent number: 11780907Abstract: The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to the influenza hemagglutinin (HA) protein, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing influenza virus activity, thus providing a means of treating or preventing influenza infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the influenza HA for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.Type: GrantFiled: January 24, 2019Date of Patent: October 10, 2023Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Lisa A. Purcell, Jonathan Viau, William Olson
-
Patent number: 11780915Abstract: The present disclosure is directed to human protease activated receptor 4 (PAR4) binding proteins (e.g. antibodies). In particular, anti-PAR4 binding proteins which are antagonists of human PAR4, as well as methods and uses thereof.Type: GrantFiled: September 11, 2018Date of Patent: October 10, 2023Assignee: MONASH UNIVERSITYInventors: Justin Hamilton, Mark Sleeman
-
Patent number: 11773163Abstract: The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of metastases. The inventors showed in vivo that lung metastasis in GPVI deficient mice are reduced compared to controls. They demonstrated that GPVI is involved in platetet interaction with tumor cells and this interaction is mediated by EMMPRIN.). Using an anti-EMMPRIN antibody, they showed that the adhesion of platelets to tumors cells is decreased. In particular, the present invention relates to a method for the prophylactic treatment of metastases in a patient suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent which inhibits the interaction between GPVI and EMMPRIN.Type: GrantFiled: November 21, 2017Date of Patent: October 3, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE STRASBOURG, ETABLISSEMENT FRANçAIS DU SANG (EFS)Inventors: Pierre Mangin, Christian Gachet
-
Patent number: 11773186Abstract: The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.Type: GrantFiled: February 16, 2021Date of Patent: October 3, 2023Assignee: MEDIMMUNE LIMITEDInventors: Andrew Buchanan, Sven Nylander, Mark Penney, Philip Newton, Feenagh Keyes, Tord Inghardt
-
Patent number: 11771743Abstract: The present invention provides methods for preventing or treating allergy. Also provided are methods for reducing the susceptibility to an allergen in a subject in need thereof. In certain embodiments, the subject has a disease or disorder selected from the group consisting of atopic dermatitis, asthma, allergic rhinitis, and eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.Type: GrantFiled: August 31, 2017Date of Patent: October 3, 2023Assignees: Regeneron Pharmaceuticals, Inc., Sanofi BiotechnolgyInventors: Jennifer D. Hamilton, Brian N. Swanson
-
Patent number: 11767359Abstract: The present disclosure provides binding agents, such as antibodies (including single chain variable fragments), that specifically bind complement component C3, including human C3, compositions comprising same, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising same.Type: GrantFiled: August 19, 2021Date of Patent: September 26, 2023Assignee: NGM Biopharmaceuticals, Inc.Inventors: Dana Yen Mei Duey, Zhonghao Liu, Jie Tang, Yan Wang, Yiyuan Yin, Wenwu Zhai, Jared Martin Higbee
-
Patent number: 11760790Abstract: Antibodies and antigen binding fragments that specifically bind to HIV-1 Env and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: GrantFiled: February 21, 2019Date of Patent: September 19, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Paolo Lusso, Qingbo Liu, Peter Kwong, John Mascola, Young Do Kwon
-
Patent number: 11753470Abstract: The disclosure provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) mediated inhibition in a PD-1 and/or TIM-3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3, thereby inhibiting PD-1 and/or TIM-3 mediated activity in said cell. The invention also provides antibodies or variants thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3.Type: GrantFiled: July 6, 2018Date of Patent: September 12, 2023Inventors: Cecilia Anna Wilhelmina Geuijen, Rinse Klooster, Cornelis Adriaan De Kruif, Paulus Johannes Tacken, Mark Throsby, Ton Logtenberg
-
Patent number: 11747351Abstract: The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated FIX protein in a test sample.Type: GrantFiled: April 14, 2020Date of Patent: September 5, 2023Assignee: BIOVERATIV THERAPEUTICS INC.Inventors: Jurg Sommer, Haiyan Jiang, Xin Zhang, Buyue Yang, Glenn Pierce
-
Patent number: 11732020Abstract: The present invention relates to the field of biotechnology. Specifically, the invention provides antigen-specific T-cell receptors (TCRs). Further, the invention encompasses polynucleotides encoding the same and vectors comprising said polynucleotides. Host cells comprising the molecules of the invention are also provided. Moreover, the invention provides means and methods for diagnostics and therapy, in particular of cancer.Type: GrantFiled: June 16, 2017Date of Patent: August 22, 2023Assignee: MEDIGENE IMMUNOTHERAPIES GMBHInventors: Christian Ellinger, Carina Wehner, Manon Weis, Susanne Wilde, Dolores Schendel
-
Patent number: 11725045Abstract: Provided are antibodies or antigen binding polypeptides characterized by the ability to neutralize respiratory syncytial virus (RSV). Specifically, the antibodies or antigen binding polypeptides are characterized by high affinity binding to RSV fusion glycoprotein (RSVF). Further provided are methods for their identification, isolation, generation, preparation, and use, as well as the heavy chain and light chain sequences of the antibodies provided.Type: GrantFiled: October 12, 2018Date of Patent: August 15, 2023Assignee: Mapp Biopharmaceutical, Inc.Inventor: Laura M. Walker